ClinicalTrials.gg
CompletedNCT07040631Updated Jul 24, 2026

Hyaluronic Acid for Prevention of Post-Intubation Sore Throat and Hoarseness

An interventional study of Endotra Gel in Breast Cancer, Postoperative Sore Throat, Cough, Hoarseness and Endotracheal Intubation, sponsored by Pusan National University Yangsan Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to find out whether applying Endotra Gel, a hyaluronic acid-based gel, to the endotracheal tube can help reduce sore throat and hoarseness after surgery.

These symptoms are common after general anesthesia when a endotracheal tube is placed into the trachea. They can cause discomfort and affect patient recovery.

The main questions this study aims to answer are:

  • Does Endotra Gel reduce the chance of having a sore throat after surgery?
  • Does it help improve hoarseness or coughing after surgery?

Participants in this study will:

  • Undergo general anesthesia for breast cancer surgery
  • Be randomly assigned to one of two groups:

    • One group will receive Endotra Gel applied to the endotracheal tube before intubation
    • The other group will have standard care with no gel
  • Be monitored for sore throat, hoarseness, and coughing right after surgery and on the day after surgery
  • Answer questions about their symptoms and satisfaction with their recovery The results will help researchers learn whether using Endotra Gel during intubation can improve patient comfort and reduce airway irritation after surgery.
02

Conditions studied

  • Breast Cancer
  • Postoperative Sore Throat, Cough, Hoarseness
  • Endotracheal Intubation
  • General Anesthesia

Keywords

  • Postoperative Sore Throat
  • Hyaluronic Acid
  • Lubricating Gel
  • Endotracheal Intubation
  • hoarseness
  • breast cancer surgery
  • randomized controlled trial
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's enrollment of 132 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Pusan National University Yangsan Hospital is the lead sponsor of 108 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 to 80 years
  • Scheduled to undergo breast cancer surgery under general anesthesia with endotracheal intubation
  • (ASA) physical status I to III

Exclusion criteria

Exclusion Criteria:

  • Mallampati classification of III or higher
  • Recent upper respiratory infection or symptoms of upper airway infection
  • Pre-existing laryngeal disease or chronic respiratory conditions (e.g., asthma, chronic bronchitis)
  • Current use of systemic
  • Refusal to provide
  • Determined to be unsuitable for study participation by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Endogra Gel Group

    Participants will receive general anesthesia for breast cancer surgery. Endotra Gel, a hyaluronic acid-based gel, will be applied evenly on the surface of the endotracheal tube cuff prior to intubation.

    Device: Endotra Gel

  • No intervention
    No Gel Group

    Participants will receive standard care for endotracheal intubation under general anesthesia without application of any gel or lubricant to the endotracheal tube.

Interventions

  • DeviceEndotra Gel

    Endotra Gel is a hyaluronic acid-based, water-soluble wound dressing gel approved by the Korean Ministry of Food and Drug Safety. In this study, it is applied to the cuff of the endotracheal tube before intubation to evaluate its effect on reducing postoperative sore throat and hoarseness.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Postoperative Sore Throat

    Postoperative sore throat (POST) will be assessed using a standardized 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) through direct patient interview. Assessment will be performed by blinded outcome assessors.

    Time frame: Up to 1 hour after extubation at PACU

Secondary outcomes

  1. Incidence and Severity of Postoperative Hoarseness

    Hoarseness will be evaluated using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) through patient interview. Evaluation will be performed by blinded assessors.

    Time frame: Up to 1 hour after extubation at PACU and on postoperative day 1 (within 24 hours after surgery)

  2. Incidence and Severity of Postoperative Cough

    Postoperative cough will be assessed on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) through direct questioning. Evaluation will be conducted by blinded assessors.

    Time frame: Up to 1 hour after extubation at PACU and on postoperative day 1 (within 24 hours after surgery)

  3. Patient Satisfaction with Intubation Experience

    Patient satisfaction regarding intubation-related discomfort will be evaluated using two structured questions: "Postoperative discomfort related to intubation interfered with daily life." "Overall, I am satisfied with the intubation experience." Each item will be rated on a 5-point Likert scale: 1 = Strongly agree, 2 = Agree, 3 = Neutral, 4 = Disagree, 5 = Strongly disagree. Responses will be collected on postoperative day 1 and analyzed as ordinal variables.

    Time frame: On postoperative day 1 (within 24 hours after surgery)

07

Study locations

1 site
  • Pusan national university yangsan hospital
    Yangsan, Gyeongsangnam-do 50612, South Korea
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07040631
Responsible party
Jung-Pil Yoon (Clinical Assistant Professor, Pusan National University Yangsan Hospital) — Principal investigator
First posted
Jun 27, 2025
Start date
Aug 6, 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Jul 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion